{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:01:30Z","timestamp":1781157690127,"version":"3.54.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cells can traffic across tissue planes and thus have considerable potential to clear disease in sanctuary sites inaccessible to alternate systemic treatments. While of great clinical benefit, this unique capability is associated with distinctive potential toxicity. Tumor inflammation-associated neurotoxicity (TIAN) is characterized by local inflammatory toxicity at tumor sites within the CNS, presumably initiated by CAR T cells penetrating the blood\u2013brain barrier (BBB). Specifically, ocular toxicity of CAR T-cell treatment affecting the retina and optic nerve may represent a variant of TIAN and has been infrequently described. We highlight a unique case of bilateral optic nerve head masses and retinopathy masquerading as fungal endophthalmitis in a patient with B-cell ALL treated with CAR T-cell therapy. With early recognition and a multidisciplinary approach, such cases of ocular TIAN can be effectively managed.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1854882","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:34Z","timestamp":1781156914000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Bilateral optic nerve head masses and retinopathy in a patient with B-cell acute lymphoblastic leukemia receiving CAR T-cell therapy masquerading as fungal endophthalmitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Jacob S.","family":"Heng","sequence":"first","affiliation":[{"name":"Retina Division, Wilmer Eye Institute, The Johns Hopkins Hospital","place":["Baltimore, MD, United States"]},{"name":"Retina Division, Shiley Eye Institute and Viterbi Family Department of Ophthalmology","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Ramos-Davila","sequence":"additional","affiliation":[{"name":"Division of Ocular Immunology, Wilmer Eye Institute, The Johns Hopkins Hospital","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra M.","family":"Maiz","sequence":"additional","affiliation":[{"name":"Retina Division, Wilmer Eye Institute, The Johns Hopkins Hospital","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Henderson","sequence":"additional","affiliation":[{"name":"Neuro-ophthalmology Division, Wilmer Eye Institute, The Johns Hopkins Hospital","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Eberhart","sequence":"additional","affiliation":[{"name":"Ocular Pathology, Wilmer Eye Institute, The Johns Hopkins Hospital","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Liberman","sequence":"additional","affiliation":[{"name":"Division of Ocular Immunology, Wilmer Eye Institute, The Johns Hopkins Hospital","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"M\u00e9tais","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Schratz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Symons","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Challice L.","family":"Bonifant","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Handa","sequence":"additional","affiliation":[{"name":"Retina Division, Wilmer Eye Institute, The Johns Hopkins Hospital","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of car t cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001450","article-title":"Bilateral retinal detachment after chimeric antigen receptor t-cell therapy","volume":"4","author":"Denton","year":"2020","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101223","article-title":"Anterior chamber infiltration of car t-cells","volume":"24","author":"Jacoby","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/hematolrep15010001","article-title":"It is in the eye of the beholder: ocular ultrasound enhanced monitoring of neurotoxicity after car-t cell therapy","volume":"15","author":"Garcia-Robledo","year":"2022","journal-title":"Hematol Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2021.10.020","article-title":"Optic neuropathy after chimeric antigen receptor t-cell therapy","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2191713","article-title":"Hit and run: bilateral massive intraocular lymphomatous infiltration after car-t therapy","volume":"32","author":"Abou-Samra","year":"2024","journal-title":"Ocul Immunol Inflammation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2333393","article-title":"Severe visual impairment following car t-cell therapy in two individuals with Malignant optic nerve infiltration","volume":"32","author":"Herr","year":"2024","journal-title":"Ocul Immunol Inflammation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000002231","article-title":"Chimeric antigen receptor-t cell-induced optic neuropathy","volume":"45","author":"Skrehot","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"355\u20139","DOI":"10.1097\/ICB.0000000000001737","article-title":"Cancer-associated retinopathy after chimeric-antigen receptor t cell therapy","volume":"20","author":"Michael","year":"2026","journal-title":"Retinal cases Brief Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000543055","article-title":"Low occurrence of ocular adverse events after car-t cell therapy","volume":"11","author":"Murty","year":"2025","journal-title":"Ocul Oncol Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of cd8+ cd19-car t cells postinfusion and the role of disease burden on outcome in pediatric b-all","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/371324","article-title":"A unique case of autoimmune retinopathy associated with anti-alpha-enolase antibodies","volume":"2011","author":"Kurz","year":"2011","journal-title":"Case Rep Ophthalmol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05409-4","article-title":"Autoimmune retinopathy: clinical, electrophysiological, and immunological features in nine patients with long-term follow-up","volume":"260","author":"Safadi","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002188","article-title":"Adverse events associated with chimeric antigen receptor t-cell therapy in ophthalmology: a narrative review","volume":"86","author":"Sarwar","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/ejh.14208","article-title":"Ocular adverse events following car-t cell therapy: a pharmacovigilance study and systematic review","volume":"113","author":"Frey","year":"2024","journal-title":"Eur J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0220","article-title":"Ocular toxicities in chimeric antigen receptor t-cell therapy: a real-world study leveraging faers database","volume":"16","author":"Zhao","year":"2024","journal-title":"Immunotherapy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of car-t cells for b-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor t-cell therapy in large b-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.06.018","article-title":"Negative prognostic impact of high-dose or long-term corticosteroid use in patients with relapsed or refractory b-cell lymphoma who received tisagenlecleucel","volume":"29","author":"Terao","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"Car t cells and t-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854882\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:41Z","timestamp":1781156921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854882\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1854882"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1854882","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1854882"}}